CureVac AG

CureVac AG

CureVac uses mRNA as an information carrier for the construction of proteins that the body can then produce itself.

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.



Activity Biomaterials, Biotechnology, Research, Medical Products, Production


Dr. Franz-Werner Haas (Chief Executive Officer)
Dr. Mariola Fotin-Mleczek
Dr. Florian von der Mülbe
Pierre Kemula, BSc
Igor Splawski, PhD


Year of foundation




Supervisory board

Baron Jean Stéphenne, MSc, MBA (Chairman)
Ralf Clemens, MD, PhD
Friedrich von Bohlen und Halbach, PhD
Mathias Hothum, PhD
Chris Tanner, PhD
Timothy M. Wright, MD
Craig A. Tooman, MBA
Dr. Viola Bronsema

Academic board

Ralf Clemens, MD, PhD (Chairman of the Scientific Advisory Board)
Professor Nina Bhardwaj, MD
Michel De Wilde, PhD
Professor Dirk Jäger, MD
Professor Karim Fizazi, MD
Christopher Karp, MD
Professor Michael P. Manns, MD
Professor Stanley Plotkin, MD
Jean-Paul Prieels, PhD
Professor Hans-Georg Rammensee, PhD
George R. Siber, MD
Professor Daniel Speiser, MD
Professor Xiao-Ning Xu, MD, PhD
Professor Fred Zepp, MD
Gerd Zettlmeissl, PhD


Current cash position of almost 900 million Euros (as of September 2020)


CureVac has GMP production facilities that comply with FDA and EMEA standards.



CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced…


CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions Expansion part of Phase 1 study…


CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK First-generation vaccine candidate, CVnCoV, to be…